¼¼°èÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀå
Therapeutic Drug Monitoring
»óǰÄÚµå : 1659379
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 93 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2030³â±îÁö 42¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 26¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 8.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 42¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ¼Ò¸ðǰÀº ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀ̸ç, CAGRÀº 8.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 35¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 6,910¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2024³â¿¡ 6¾ï 6,910¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 12.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.0%¿Í 7.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ä¡·áÁ¦ ¸ð´ÏÅ͸µÀº ¾î¶»°Ô ¸ÂÃãÇü ÀǷḦ ÃÖÀûÈ­Çϰí Àִ°¡?

¾à¹° ¸ð´ÏÅ͸µ(TDM)Àº ȯÀÚÀÇ Ç÷Áß ¾à¹° ³óµµ¸¦ ÃøÁ¤ÇÏ¿© È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ¿ë·®À» º¸ÀåÇÏ´Â ÀÓ»ó °úÁ¤À¸·Î, Ç×°£Áú¾à, Ç×»ýÁ¦, Ç×Á¤½Åº´¾à, ¸é¿ª¾ïÁ¦Á¦ µî Ä¡·á ¹üÀ§°¡ Á¼Àº ¾à¹°À» °ü¸®ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¾à¹° ³óµµ¸¦ ÃßÀûÇÔÀ¸·Î½á ÀÇ·áÁøÀº È¿´ÉÀ» ÃÖÀûÈ­ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¿ë·®À» Á¶ÀýÇÒ ¼ö ÀÖÀ¸¸ç, TDMÀº °³º° ȯÀÚÀÇ ¹ÝÀÀ, À¯ÀüÀû ¿äÀÎ, ÀáÀçÀû ¾à¹° »óÈ£ÀÛ¿ë¿¡ ´ëÀÀÇÏ°í ¸¸¼ºÁúȯ ¹× º¹ÀâÇÑ º´Å»ý¸®¿¡¼­ Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

Á¦Ç° À¯Çü¿¡´Â ¼Ò¸ðǰ, Àåºñ, ¼ÒÇÁÆ®¿þ¾î°¡ Æ÷ÇԵ˴ϴÙ. ½Ã¾à, ŰƮ, ±³Á¤ Åø¿Í °°Àº ¼Ò¸ðǰÀº °Ë»ç ¹× ºÐ¼®¿¡ ¹Ýº¹ÀûÀ¸·Î »ç¿ëµÇ¹Ç·Î °¡Àå Å« ºÎ¹®À» Â÷ÁöÇÕ´Ï´Ù. Àåºñ¿¡´Â ¾à¹° ³óµµ¸¦ °¨ÁöÇÏ´Â ºÐ¼®±â ¹× °Ë»ç Àåºñ°¡ Æ÷ÇԵǸç, ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº µ¥ÀÌÅ͸¦ °ü¸®ÇÏ°í º¹¿ë·® ±ÇÀå·®À» ÃÖÀûÈ­ÇÏ´Â ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÌ Æ÷ÇԵǸç, TDMÀ¸·Î ¸ð´ÏÅ͸µµÇ´Â ¾à¹° À¯Çü¿¡´Â Ç×°æ·ÃÁ¦, ¸é¿ª¾ïÁ¦Á¦, Ç×»ýÁ¦, Ç×Á¤½Åº´¾à µîÀÌ ÀÖ½À´Ï´Ù. Ç×°æ·ÃÁ¦´Â ¹ßÀÛÀ» ¿¹¹æÇϰí ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ ¿ë·® °ü¸®°¡ ¸Å¿ì Áß¿äÇϹǷΠ°¡Àå Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖÀ¸¸ç, TDMÀÇ ÃÖÁ¾»ç¿ëÀڷδ º´¿ø, Áø´Ü ½ÇÇè½Ç, Àü¹® Ŭ¸®´ÐÀÌ ÀÖ½À´Ï´Ù. º´¿øÀº ¸¸¼ºÁúȯ, Àå±âÀ̽Ä, ¾Ï Ä¡·á µî Á¤È®ÇÑ ¾à¹° ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ±¤¹üÀ§ÇÑ ¾à¹°¿ä¹ýÀ» °ü¸®Çϰí ÀÖÀ¸¸ç, ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. Áø´Ü¿¬±¸¼Ò´Â ÀûÀýÇÑ ¿ë·® Á¶Á¤°ú ¾àÈ¿¸¦ °ü¸®Çϱâ À§ÇØ ÀÏ»óÀûÀ¸·Î TDM °Ë»ç¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. °£Áú, ÀÚ°¡¸é¿ªÁúȯ µîÀÇ Áõ»ó¿¡ ´ëÀÀÇÏ´Â Àü¹® Ŭ¸®´Ð¿¡¼­´Â ȯÀÚÀÇ Ä¡·á¸¦ ¸ÂÃãÈ­Çϰí Ä¡·á ¼ºÀûÀ» Çâ»ó½Ã۱â À§ÇØ TDMÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

Ä¡·áÁ¦ ¸ð´ÏÅ͸µÀº ÀÇ·á¼­ºñ½º¿¡ ¾î¶»°Ô ÅëÇյǰí Àִ°¡?

º´¿ø¿¡¼­´Â Àå±âÀ̽Ä, °£Áú, Á¤½ÅÁúȯ µîÀÇ ¾à¹° °ü¸®¿¡ TDMÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¾à¹°ÀÇ ÃÖÀûÀÇ ¼º´ÉÀ» º¸ÀåÇϸ鼭 ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. Áø´Ü ½ÇÇè½Ç¿¡¼­´Â TDMÀ» Ȱ¿ëÇÏ¿© Ç÷¾× »ùÇÃÀÇ ¾à¹° ³óµµ¸¦ ºÐ¼®ÇÏ¿© ÀÓ»óÀÇ¿¡°Ô ¿ë·®À» ¹Ì¼¼ Á¶Á¤ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. Àü¹® Ŭ¸®´Ð¿¡¼­ TDMÀº ȯÀÚÀÇ ¹ÝÀÀ°ú ´ë»çÀ²¿¡ µû¶ó ¿ë·®À» Á¶Á¤ÇÏ¿© º¹ÀâÇÑ ¾à¼öó¸®ÀÇ ¸ÂÃã Ä¡·á °èȹÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß ºÐ¾ß¿¡¼­ TDMÀº ÀÓ»ó½ÃÇè ¹× ÀǾàǰ °³¹ßÀ» Áö¿øÇÏ¿© Åõ¿© ¿ä¹ýÀ» °³¼±ÇÏ°í ½Å¾àÀÇ ¾ÈÀü¼ºÀ» °ËÁõÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¾à¹° ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ºÀåÀº ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤Åà Áõ°¡, ¸¸¼ºÁúȯÀÇ ¹ß»ý·ü Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÚµ¿ ºÐ¼®±â, Point-of-Care ±â±â, AI ±â¹Ý ¼ÒÇÁÆ®¿þ¾î¿Í °°Àº ±â¼ú Çõ½ÅÀ¸·Î º´¿ø ¹× ÀçÅÃÄ¡·á ȯ°æ¿¡¼­ TDMÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, TDMÀº ¾à¼öó¸®ÀÇ ÃÖÀûÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇϹǷΠȯÀÚ ¾ÈÀü, Á¤È®ÇÑ Åõ¾à, ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ¸é¼­ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë, ¾à¹°À¯ÀüüÇÐ ¿¬±¸ÀÇ È°¼ºÈ­, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á°¡ °è¼Ó È®»êµÊ¿¡ µû¶ó TDMÀº ȯÀÚ ¸ÂÃãÇü ÀÇ·á¿¡ Á¡Á¡ ´õ ÇʼöÀûÀÎ ¿ä¼Ò°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(¼Ò¸ðǰ,±â±â); ±â¼ú(¸é¿ªÃøÁ¤¹ý,Å©·Î¸¶Åä±×·¡ÇÇ MS); ÃÖÁ¾»ç¿ëÀÚ(º´¿ø°Ë»ç½Ç,»ó¾÷/¹Î°£°Ë»ç½Ç,±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 42»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Therapeutic Drug Monitoring Market to Reach US$4.2 Billion by 2030

The global market for Therapeutic Drug Monitoring estimated at US$2.6 Billion in the year 2024, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Therapeutic Drug Monitoring Consumables, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Therapeutic Drug Monitoring Equipment segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$669.1 Million While China is Forecast to Grow at 12.6% CAGR

The Therapeutic Drug Monitoring market in the U.S. is estimated at US$669.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Therapeutic Drug Monitoring Market - Key Trends and Drivers Summarized

How Is Therapeutic Drug Monitoring Optimizing Personalized Medicine?

Therapeutic Drug Monitoring (TDM) is a clinical process that measures drug concentrations in patients' blood to ensure effective and safe dosages. TDM is crucial for managing medications with narrow therapeutic ranges, including antiepileptics, antibiotics, antipsychotics, and immunosuppressants. By tracking drug levels, healthcare providers can adjust dosages to optimize efficacy and minimize side effects, making TDM a cornerstone of personalized medicine. It helps cater to individual patient responses, genetic factors, and potential drug interactions, improving treatment outcomes across chronic diseases and complex conditions.

What Are the Key Segments in the Therapeutic Drug Monitoring Market?

Product types include consumables, devices, and software. Consumables—like reagents, kits, and calibration tools—represent the largest segment due to their recurring use in testing and analysis. Devices encompass analyzers and testing equipment that detect drug concentrations, while software solutions manage data and optimize dosage recommendations. Drug classes monitored through TDM include antiepileptics, immunosuppressants, antibiotics, and antipsychotics. Among these, antiepileptics hold a significant share due to the critical need for dose management to prevent seizures and ensure patient safety. End-users of TDM include hospitals, diagnostic laboratories, and specialty clinics. Hospitals lead the market as they manage a wide range of drug therapies for chronic diseases, organ transplants, and cancer treatments, all of which require precise drug monitoring. Diagnostic labs conduct routine TDM tests to ensure proper dosage adjustments and manage drug efficacy. Specialty clinics, which cater to conditions like epilepsy and autoimmune disorders, rely on TDM to customize patient care and improve outcomes.

How Is Therapeutic Drug Monitoring Integrated in Healthcare?

In hospitals, TDM is essential for managing medications in conditions like organ transplants, epilepsy, and psychiatric disorders. It reduces the risk of adverse effects while ensuring optimal drug performance. Diagnostic laboratories utilize TDM to analyze blood samples for drug concentrations, providing clinicians with critical data to fine-tune dosages. In specialty clinics, TDM supports personalized treatment plans for complex drug therapies, adjusting doses based on patient responses and metabolic rates. Additionally, in research, TDM aids clinical trials and drug development, where it is used to refine dosage regimens and validate the safety of new pharmaceuticals.

What Factors Are Driving the Growth in the Therapeutic Drug Monitoring Market?

The growth in the Therapeutic Drug Monitoring market is driven by several factors, including the rising adoption of personalized medicine, increasing incidence of chronic diseases, and advancements in diagnostic technologies. Innovations like automated analyzers, point-of-care devices, and AI-based software have expanded TDM applications in hospitals and home healthcare settings. The focus on improving patient safety, ensuring accurate dosing, and reducing healthcare costs has further fueled demand, as TDM plays a critical role in optimizing drug therapy. Additionally, expanding healthcare infrastructure, growing pharmacogenomics research, and regulatory support for precision medicine have contributed to the market's growth. As personalized medicine continues to gain traction, TDM is expected to become increasingly integral to individualized patient care.

SCOPE OF STUDY:

The report analyzes the Therapeutic Drug Monitoring market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Consumables, Equipment); Technology (Immunoassays, Chromatography-MS); End-Use (Hospital Laboratories, Commercial / Private Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â